
Lyell Immunopharma (LYEL) Stock Forecast & Price Target
Lyell Immunopharma (LYEL) Analyst Ratings
Bulls say
Lyell Immunopharma has demonstrated strong financial positioning with cash, cash equivalents, and marketable securities totaling $320 million at the end of the quarter, an increase from $297 million in the previous quarter, primarily driven by a private placement. The company’s advancements in its product pipeline, notably the promising data from LYL273 indicating durability in treating complex solid tumors, bolster investor confidence in its technological leadership within the CAR-T market. Additionally, rising probabilities of approval for key candidates such as DLBCL and positive expert feedback further underpin the company's growth potential, reflecting a compelling investment narrative.
Bears say
Lyell Immunopharma's financial outlook is negatively impacted by a decrease in research and development expenditure, which fell to $28.2 million in the third quarter of 2025 from $34.9 million in the second quarter, indicating potential challenges in advancing its product pipeline. Significant risks loom over the company's ability to penetrate the CAR-T market effectively, particularly against existing CD19 CAR-T therapies, as well as concerns regarding the efficacy of its treatments and potential safety events that could alter their risk-benefit profiles. Additionally, the lack of definitive data illustrating long-term durability and manageable toxicity in larger patient populations raises doubts about the viability of LYL273 as a standard-of-care therapy, hindering investor confidence.
This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.
Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction
Start investing in Lyell Immunopharma (LYEL)
Order type
Buy in
Order amount
Est. shares
0 shares